Sarepta Therapeutics Inc (SRPT)

Cash ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Cash and cash equivalents	US$ in thousands	427,300	428,430	541,932	851,929	871,668	966,777	1,038,620	868,565	1,233,880	2,115,870	1,599,110	1,697,280	1,481,840	1,502,650	1,474,640	1,639,960	1,764,210	835,080	724,829	808,591
Short-term investments	US$ in thousands	963,500	1,247,820	1,191,610	1,008,790	1,010,430	1,022,600	1,033,900	1,059,450	779,548	0	0	30,000	255,997	435,923	341,467	421,349	406,940	289,668	324,063	294,478
Total current liabilities	US$ in thousands	608,709	653,659	450,743	498,654	536,884	619,604	602,916	545,566	454,962	452,733	373,443	425,022	364,736	416,026	378,388	354,896	306,429	264,767	215,856	162,089
Cash ratio		2.28	2.56	3.85	3.73	3.51	3.21	3.44	3.53	4.43	4.67	4.28	4.06	4.76	4.66	4.80	5.81	7.09	4.25	4.86	6.81

March 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($427,300K + $963,500K) ÷ $608,709K
= 2.28

The cash ratio of Sarepta Therapeutics Inc has shown a fluctuating trend over the past several quarters. The company's cash ratio has generally remained above 2, indicating a strong ability to cover its short-term liabilities with its cash and cash equivalents.

There was a notable increase in the cash ratio from the end of 2019 to mid-2020, reaching a peak of 7.09 by the end of March 2020. This indicates a significant buildup of cash relative to the company's current liabilities during that period.

Subsequently, the cash ratio decreased gradually but remained relatively stable around the 4 to 5 range for the following quarters. This suggests that Sarepta Therapeutics Inc continued to maintain a comfortable level of cash reserves compared to its short-term obligations.

Overall, the company's cash ratio indicates a healthy liquidity position, with a relatively high level of cash reserves compared to its short-term liabilities throughout the periods analyzed.